MESOTHELIOMA CANCER - D7988C00001

This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma.

For more information please visit: https://clinicaltrials.gov/study/NCT06097728?term=D7988C00001&rank=1